Under Pressure: Sanofi Joins Call For Price Transparency
As Sanofi joined the ranks of pharma companies pledging to limit annual US price increases, the company also released average aggregate list and net prices in 2016, showing net prices declined 2.1%.
You may also be interested in...
For every $100 spent at retail pharmacies, $41 accrues to the manufacturer and $41 accrues to intermediaries in the distribution system, according to a new study on US prescription drug spending, though drug manufacturers hold onto more profit.
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
While other companies have promised not to raise their drug prices beyond 10%, Sanofi is using the rate of medical inflation (expected to be 5.4% in 2017) in setting its annual list price hikes. Company retains option to increase prices beyond benchmark.